Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Issues Untitled Letter To Australia's CSL Biotherapies For GMP Deviations For Flu Vaccine

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - U.S. FDA's Center for Biologics issued an Untitled Letter June 24 to CSL Biotherapies for deviations from current good manufacturing practices at its manufacturing plant in the Australian state of Victoria
Advertisement

Related Content

Australia's CSL Slapped With U.S. FDA Warning Letter Over Flu Vaccine
Australia's CSL Slapped With U.S. FDA Warning Letter Over Flu Vaccine
CSL Bullish on Immunoglobulins, Bearish On Plasma Pricing
CSL Bullish on Immunoglobulins, Bearish On Plasma Pricing
CSL Invests $235 Million In Manufacturing Facility For Late-stage Development In Australia
CSL Invests $235 Million In Manufacturing Facility For Late-stage Development In Australia
Australia's CSL Withdraws Seasonal Trivalent Flu Vaccine For Children Under 5
Australia's CSL Withdraws Seasonal Trivalent Flu Vaccine For Children Under 5
CSL's Seasonal Flu Vaccine Halted In Kids Under 5 Following Spike In Adverse Events In West Australian Children
Advertisement
UsernamePublicRestriction

Register

SC075250

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel